Drug Safety
David Liew drdavidliew
2 years 4 months ago
New 2023 @eular_org SLE recommendations
Key changes, in response to evidence:
- more caution re: steroids
- biologics earlier
- combo therapy (BEL or CNI/VCS) considered for lupus nephritis
#EULAR2023 @RheumNow https://t.co/J3Lp8owRyT
Bella Mehta bella_mehta
2 years 4 months ago
#EULAR2023 recommendation update summary from the 2018 in #PsA whats new!
- 3 more drugs now available in PsA. – Guselkumab, Upadacitnib, Risankizumab (1 more in the pipeline)
- safety now to to considered!
- consider the full picture - extraarticular manifestations
@rheumnow https://t.co/7GBILtCX4i
David Liew drdavidliew
2 years 4 months ago
Obviously lots of real world data at #EULAR2023 on JAKi safety (cardiovascular & cancer, see ORAL Surveillance).
Real problem:
many still have shorter follow-up periods. Cancer in particular takes time. It’s great to see data now, but:
*longer follow-up needed* +++
@RheumNow https://t.co/YH4fZgNQjY
Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.
A nationwide population-based study, by Beydon et al. (OP0044), has performed a more recent (2010-2020) analysis of cancer incidence in people living with RA within the French national claim database, compared to general population, measured in the French Network of Population-Based Cancer Registries.
Risk of poor pregnancy outcomes in lupus patients continues to remain high, especially in the setting of high disease activity. Preliminary data from a lupus pregnancy LEGACY cohort presented at EULAR 2023 raise concern.
Dr. John Cush RheumNow
2 years 4 months ago
An update on JAK inhibitors and cardiovascular risks
Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors.
https://t.co/yZqHEg73bn https://t.co/CzVH62LEgL
Dr. John Cush RheumNow
2 years 4 months ago
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Dr Gurdeep Dulay gurdeep_dulay
2 years 4 months ago
✅Benefit of adding #HydroxyChloroquine #HCQ in refractory obstetric #APS
#EULAR2023 poster https://t.co/dgGY496dbh
Dr. Antoni Chan synovialjoints
2 years 4 months ago
Factors related to having a flare of arthritis during COVID-19 include female gender, higher disease activity, no DMARD at time of vaccination. Stopping DMARDs need to be weighed up against risk of flares, Pedro Machado, COVID-19 #EULAR2023 @RheumNow https://t.co/3sd32tF2kW
Poster Hall